News

A research team from the University of Exeter Medical School and King’s College London has uncovered strong evidence of neurological epigenetic changes leading to Alzheimer Disease (AD) development. There are over 26 million people affected by AD worldwide, a chronic neurodegenerative disorder characterized by progressive neuropathology and cognitive decline. Despite…

An intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease has been successfully performed by Stemedica International, a subsidiary of Stemedica Cell Technologies, developing stem cell therapies for Alzheimer’s disease and dementia. The first results of the…

Researchers from the Blanchette Rockefeller Neuroscience Institute (BRNI) have gathered evidence of the possible role of protein kinase C epsilon (PKCe) in the treatment of Alzheimer’s disease (AD). The news was recently announced by Neurotrope, a pharmaceutical company collaborating with BRNI in the development of bryostatin, a potent modulator of PKCe,…

Individuals with frontotemporal degeneration (FTD) may soon benefit from research priorities directed toward curing Alzheimer’s disease and other forms of dementia. The Association of Frontotemporal Degeneration (AFTD) broke word of plans to formally include FTD in national research priorities by the year 2025. According to AFTD Executive Director Susan…